Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…Abstract Number: 2825 • 2013 ACR/ARHP Annual Meeting
The Influence Of Early Menopause On Cardiovascular Risk In Women With Rheumatoid Arthritis
Background/Purpose: Lifetime exposure to female sex hormones may play a role in the development and severity of rheumatoid arthritis (RA). These same hormones have also…Abstract Number: 1749 • 2013 ACR/ARHP Annual Meeting
Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction
Background/Purpose: , Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and…Abstract Number: 895 • 2013 ACR/ARHP Annual Meeting
The Relative Risk Of Aortic Aneurysm In Patients With Giant Cell Arteritis Compared With The General Population
Background/Purpose: To evaluate the risk of aortic aneurysm in patients with giant cell arteritis (GCA) when compared with age, gender and location matched controls from…Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…Abstract Number: 358 • 2013 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The 2-Year Prospective Cohort Study
Background/Purpose: Rheumatoid arthritis (RA) patients have increased prevalence of carotid atherosclerosis, especially plaque formation, which has been associated with inflammatory burden in a previous study.…Abstract Number: 2826 • 2013 ACR/ARHP Annual Meeting
Performance Of Five Current Risk Algorithms In Predicting Cardiovascular Events In Rheumatoid Arthritis Patients
Background/Purpose: Cardiovascular risk in rheumatoid arthritis (RA) is increased. The cardiovascular (CV) risk algorithms used in the general population may underestimate the risk of cardiovascular…Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…Abstract Number: 2828 • 2013 ACR/ARHP Annual Meeting
The Performance Of The Original and An Updated Cardiovascular Risk Algorithm (SCORE) In Patients With Rheumatoid Arthritis
Background/Purpose: Cardiovascular (CV) risk in rheumatoid arthritis (RA) is increased. The CV risk algorithms for the general population may underestimate the risk of cardiovascular disease…Abstract Number: 1709 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Background/Purpose: Although rheumatoid arthritis (RA) increases cardiovascular disease (CVD) risk, RA patients receive less CVD preventive care than peers. We previously showed gaps in lipid…Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 38
- Next Page »